American CryoStem to Present at OneMedForumNY 2013
26 Giugno 2013 - 3:35PM
American CryoStem Corporation (OTCQB:CRYO), a
leading strategic developer, marketer and global licensor of
patented adipose tissue-based cellular technologies for the
Regenerative and Personalized Medicine industries, today announced
that the Company has been invited to present at OneMedForumNY 2013
to be held at the Metropolitan Club in New York City, June 26-27,
2013.
OneMedForumNY 2013 will feature over 40 private and public
companies with sector-altering technology and a growing reputation.
Technologies at the benchtop level will present alongside
revenue-positive market-stage companies. The forum is a
gathering of leading investors and management of some of the most
promising emerging life science companies in Asia and North
America. Through panels, workshops and up-close programming
with top industry leaders, attendees will explore strategies for
company growth, and finance with healthcare investors looking for
outsized returns.
EVENT AT A GLANCE |
|
|
|
WHO: |
John Arnone – Chairman and CEO |
|
Anthony Dudzinski – COO |
|
|
WHEN: |
Thursday, June 27, 2013 |
|
2:50PM ET |
|
|
WHERE: |
The Metropolitan Club |
|
Morton Room |
|
One East 60th Street |
|
New York, New York |
About OneMedForum
Launched in 2010 by OneMedPlace, OneMedForumNY includes an
audience of institutional investors, high net worth individual
investors, family offices, business development executives
throughout the US and Europe building and financing high growth
medical technology, healthcare and life science companies. For
more information, visit
www.onemedplace.com/forum/.
About American CryoStem Corporation
A pioneer in the fields of Regenerative and Personalized
Medicine, American CryoStem is a developer, marketer and global
licensor of patented adipose tissue based cellular technologies and
related proprietary services with a focus on clinical processing,
commercial bio-banking and application development for adipose
(fat) tissue and autologous adipose-derived regenerative cells
(ADRCs). The Company maintains a strategic portfolio of
intellectual property and patent applications that form its Adipose
Tissue Processing Platform, which supports and promotes a growing
pipeline of biologic products and processes, clinical services and
international licensing opportunities. Through its ACS
Laboratories division, the Company operates an FDA registered, cGMP
compliant human tissue processing, cryo-storage and cell culture
and differentiation media development facility in Mount Laurel, New
Jersey. For more information, please visit
www.americancryostem.com and
www.acslaboratories.com.
CONTACT: FOR MORE INFORMATION:
Hanover|Elite
Kathy Addison, Chief Operating Officer
407-585-1080 or via email at CRYO@hanoverelite.com
Grafico Azioni American Cryostem (CE) (USOTC:CRYO)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni American Cryostem (CE) (USOTC:CRYO)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a American Cryostem Corporation (CE) (OTCMarkets): 0 articoli recenti
Più American CryoStem Corp. Articoli Notizie